title: Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
authors.affiliation: Duke University, USA.
authors.forename: W K
authors.initials: WK
authors.lastname: Viscusi
authors.forename: S R
authors.initials: SR
authors.lastname: Rowland
authors.forename: H L
authors.initials: HL
authors.lastname: Dorfman
authors.forename: C J
authors.initials: CJ
authors.lastname: Walsh
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000592:standards; D007885:Legislation, Pharmacy / Q000191:economics; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration; D026712:Value of Life